DiaMedica Therapeutics Receives Health Canada Clearance to Initiate Phase 2 Study of DM199 in Preeclampsia
DiaMedica Therapeutics Inc. (DMAC)
Last diamedica therapeutics inc. earnings: 11/13 04:12 pm
Check Earnings Report
Company Research
Source: Business Wire
“No Objection Letter” from Health Canada enables initiation of Phase 2 DM199 study in early-onset preeclampsiaDM199 Preeclampsia program featured in recent National Public Radio (NPR) coverage MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke (AIS), today announced that it has received a No Objection Letter (NOL) from Health Canada for its Clinical Trial Application to evaluate DM199 in a Phase 2 trial in patients with early-onset preeclampsia (PE). This regulatory clearance enables DiaMedica to initiate its Phase 2 study of DM199 in early-onset preeclampsia. The Company plans to initiate the trial in 2026 and expand into the United States and United Kingdom as regulatory clearances are obtained.“Health Canada’s authorization to initiate our Phase 2 clinical trial of DM199 in preeclampsia represents an importa
Show less
Read more
Impact Snapshot
Event Time:
DMAC
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
DMAC alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
DMAC alerts
High impacting DiaMedica Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
DMAC
News
- DiaMedica Therapeutics Receives Health Canada Clearance to Initiate Phase 2 Study of DM199 in Preeclampsia [Yahoo! Finance]Yahoo! Finance
- Acute Ischemic Stroke Market Poised for Expansion During the Forecast Period (2026–2036) as Innovative Treatment Modalities Gain Momentum | DelveInsight [Yahoo! Finance]Yahoo! Finance
- DiaMedica Therapeutics to Participate in Upcoming March Investor Conferences [Yahoo! Finance]Yahoo! Finance
- DiaMedica Therapeutics to Participate in Upcoming March Investor ConferencesBusiness Wire
- DiaMedica Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business Wire
DMAC
Earnings
- 11/12/25 - Miss
DMAC
Analyst Actions
- 1/5/26 - Lake Street Capital
DMAC
Sec Filings
- 2/17/26 - Form SCHEDULE
- 2/17/26 - Form SCHEDULE
- 2/6/26 - Form SCHEDULE
- DMAC's page on the SEC website